EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer

S Daniel Haldar iD, Fen Saj, So Jung Hong, Rishi Surana, Lianchun Xiao, J Jack Lee, Brandon Smaglo, Dan Zhao iD, Huili Zhu, Ryan Huey, Jason Willis iD, M Pia Morelli und 7 weitere

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag071 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Oncologist, 2026. Verfasst von S Daniel Haldar und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Hauptthemen laut MEDLINE: Hydroxychloroquine, Pancreatic Neoplasms, Benzimidazoles, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer, Pancreatic Cancer Action Network-AACR Research Acceleration Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dual mitogen-activated protein kinase (MAPK) pathway and autophagy inhibition show synergistic antitumor activity in preclinical models of RAS-mutant cancers. We hypothesized that autophagy blockade with hydroxychloroquine (HCQ) could overcome resistance to MEK inhibition with binimetinib (BINI) and provide clinical benefit in previously treated, KRAS-mutated, metastatic pancreatic ductal adenocarcinoma (PDAC).

Methods

This investigator-led, single-arm, open-label, phase I dose escalation/expansion trial evaluated the safety and tolerability of BINI + HCQ in patients with previously treated, metastatic PDAC (NCT04132505). Key eligibility criteria: ECOG 0-1, adequate organ function, ≥1 prior line of therapy for metastatic disease, and presence of KRAS mutation. Dose escalation followed a Bayesian optimal interval design. The primary endpoint was the maximum-tolerated dose (MTD). Secondary endpoints included safety, objective response rate (ORR), disease control rate (DCR), progression-free survival, and overall survival (OS).

Results

From December 2019 to August 2024, 34 patients were enrolled in dose escalation (n = 17) and dose expansion (n = 17). Two dose-limiting toxicities occurred among the first 3 patients treated at dose level 1 (BINI 45 mg + HCQ 600 mg): grade 3 creatine phosphokinase elevation with renal impairment (BINI) and grade 3 QT prolongation (HCQ). Following dose de-escalation due to poor tolerance, the MTD was determined to be BINI 30 mg + HCQ 600 mg twice daily and used in the expansion. Out of 31 response-evaluable patients, 2 patients achieved a partial response and 9 patients achieved stable disease, yielding ORR 6.5% and DCR 35.5%, respectively. Median progression-free survival was 1.9 months, and median OS was 5.3 months.

Conclusion

The combination of BINI + HCQ demonstrated a challenging toxicity profile and limited clinical activity in patients with chemorefractory metastatic PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxychloroquinePancreatic NeoplasmsBenzimidazolesAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalHumansFemaleMaleMiddle AgedAgedMaximum Tolerated DoseAdultAged, 80 and over

Stichwörter der Autor:innen

KRASMEK inhibitionautophagyhydroxychloroquinepancreatic cancer

Substanzen

HydroxychloroquineBenzimidazolesbinimetinib

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, United States.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States.
  • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States.
  • Merck & Co., Inc, North Wales, PA, 19454, United States.
  • Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States.

ORCID-Profile: S Daniel Haldar, Dan Zhao, Jason Willis, Robert Wolff

Förderung

  • Pfizer
  • Pancreatic Cancer Action Network-AACR Research Acceleration Network

Zitieren

APA

Haldar, S. D., Saj, F., Hong, S. J., Surana, R., Xiao, L., Lee, J. J., Smaglo, B., Zhao, D., Zhu, H., Huey, R., Willis, J., Morelli, M. P., Overman, M., McAllister, F., Wolff, R., Maitra, A., Fogelman, D., Der, C., & Pant, S. (2026). Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyag071

Vancouver

Haldar SD, Saj F, Hong SJ, Surana R, Xiao L, Lee JJ, et al. Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. The Oncologist. 2026. doi:10.1093/oncolo/oyag071

BibTeX
@article{Haldar2026,
  author = {Haldar, S Daniel and Saj, Fen and Hong, So Jung and Surana, Rishi and Xiao, Lianchun and Lee, J Jack and Smaglo, Brandon and Zhao, Dan and Zhu, Huili and Huey, Ryan and Willis, Jason and Morelli, M Pia and Overman, Michael and McAllister, Florencia and Wolff, Robert and Maitra, Anirban and Fogelman, David and Der, Channing and Pant, Shubham},
  title = {Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag071}
}
Kostenlos starten →